Home > Publications database > Site-Specific Considerations on Engineered T Cells for Malignant Gliomas. > print

001     180794
005     20240229145632.0
024 7 _ |a 10.3390/biomedicines10071738
|2 doi
024 7 _ |a pmid:35885047
|2 pmid
024 7 _ |a altmetric:132861493
|2 altmetric
037 _ _ |a DKFZ-2022-01556
041 _ _ |a English
082 _ _ |a 570
100 1 _ |a Elmadany, Nirmeen
|0 P:(DE-He78)7aa3ba111f340c5cfbed338d0d8fb4ca
|b 0
|e First author
|u dkfz
245 _ _ |a Site-Specific Considerations on Engineered T Cells for Malignant Gliomas.
260 _ _ |a Basel
|c 2022
|b MDPI
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1698998203_23211
|2 PUB:(DE-HGF)
|x Review Article
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a #EA:D170#LA:D170# / HI-TRON
520 _ _ |a Immunotherapy has revolutionized cancer treatment. Despite the recent advances in immunotherapeutic approaches for several tumor entities, limited response has been observed in malignant gliomas, including glioblastoma (GBM). Conversely, one of the emerging immunotherapeutic modalities is chimeric antigen receptors (CAR) T cell therapy, which demonstrated promising clinical responses in other solid tumors. Current pre-clinical and interventional clinical studies suggest improved efficacy when CAR-T cells are delivered locoregionally, rather than intravenously. In this review, we summarize possible CAR-T cell administration routes including locoregional therapy, systemic administration with and without focused ultrasound, direct intra-arterial drug delivery and nanoparticle-enhanced delivery in glioma. Moreover, we discuss published as well as ongoing and planned clinical trials involving CAR-T cell therapy in malignant glioma. With increasing neoadjuvant and/or adjuvant combinatorial immunotherapeutic concepts and modalities with specific modes of action for malignant glioma, selection of administration routes becomes increasingly important.
536 _ _ |a 314 - Immunologie und Krebs (POF4-314)
|0 G:(DE-HGF)POF4-314
|c POF4-314
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650 _ 7 |a CAR T cells
|2 Other
650 _ 7 |a CARs
|2 Other
650 _ 7 |a FUS
|2 Other
650 _ 7 |a glioblastoma
|2 Other
650 _ 7 |a glioma
|2 Other
650 _ 7 |a intrathecal delivery
|2 Other
650 _ 7 |a nanotechnology
|2 Other
650 _ 7 |a systemic delivery
|2 Other
700 1 _ |a Alhalabi, Obada
|0 P:(DE-He78)98da1f9d3c5ced2d8867edfe9f681ddc
|b 1
|u dkfz
700 1 _ |a Platten, Michael
|0 P:(DE-He78)5ef8651b0f857b9c640aa5b1498c43b5
|b 2
|u dkfz
700 1 _ |a Bunse, Lukas
|0 P:(DE-He78)e579130c57e8c686ed1c2dedfa595985
|b 3
|e Last author
|u dkfz
773 _ _ |a 10.3390/biomedicines10071738
|g Vol. 10, no. 7, p. 1738 -
|0 PERI:(DE-600)2720867-9
|n 7
|p 1738
|t Biomedicines
|v 10
|y 2022
|x 2227-9059
909 C O |p VDB
|o oai:inrepo02.dkfz.de:180794
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 0
|6 P:(DE-He78)7aa3ba111f340c5cfbed338d0d8fb4ca
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 1
|6 P:(DE-He78)98da1f9d3c5ced2d8867edfe9f681ddc
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 2
|6 P:(DE-He78)5ef8651b0f857b9c640aa5b1498c43b5
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 3
|6 P:(DE-He78)e579130c57e8c686ed1c2dedfa595985
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-314
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Immunologie und Krebs
|x 0
914 1 _ |y 2022
915 _ _ |a Creative Commons Attribution CC BY (No Version)
|0 LIC:(DE-HGF)CCBYNV
|2 V:(DE-HGF)
|b DOAJ
|d 2020-08-22
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2020-08-22
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2020-08-22
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2020-08-22
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2020-08-22
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2020-08-22
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2022-11-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2022-11-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2022-01-07T14:28:55Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2022-01-07T14:28:55Z
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Blind peer review
|d 2022-01-07T14:28:55Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2022-11-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2022-11-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2022-11-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2022-11-11
920 2 _ |0 I:(DE-He78)D170-20160331
|k D170
|l KKE Neuroimmunologie und Hirntumorimmunologie
|x 0
920 1 _ |0 I:(DE-He78)D170-20160331
|k D170
|l KKE Neuroimmunologie und Hirntumorimmunologie
|x 0
920 1 _ |0 I:(DE-He78)HD01-20160331
|k HD01
|l DKTK HD zentral
|x 1
920 1 _ |0 I:(DE-He78)B067-20160331
|k B067
|l B067 Juniorgruppe Brain Tumor Translational Target
|x 2
920 0 _ |0 I:(DE-He78)D170-20160331
|k D170
|l KKE Neuroimmunologie und Hirntumorimmunologie
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)D170-20160331
980 _ _ |a I:(DE-He78)HD01-20160331
980 _ _ |a I:(DE-He78)B067-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21